ABBV Acquires APGE
AbbVie is acquiring Apogee for $135.11 per share in cash to expand its pipeline of clinical-stage candidates for inflammatory and immunological diseases
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.